nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—VEGFA—liver cancer	0.28	0.507	CbGaD
Carvedilol—CYP2E1—liver cancer	0.137	0.248	CbGaD
Carvedilol—CYP1A1—liver cancer	0.135	0.245	CbGaD
Carvedilol—XDH—Doxorubicin—liver cancer	0.0728	0.46	CbGbCtD
Carvedilol—CYP1A2—Sorafenib—liver cancer	0.0156	0.0987	CbGbCtD
Carvedilol—CYP2C9—Sorafenib—liver cancer	0.0141	0.0889	CbGbCtD
Carvedilol—ABCB1—Sorafenib—liver cancer	0.0137	0.0863	CbGbCtD
Carvedilol—CYP2D6—Sorafenib—liver cancer	0.0129	0.0813	CbGbCtD
Carvedilol—SELE—umbilical vein—liver cancer	0.0103	0.273	CbGeAlD
Carvedilol—VCAM1—umbilical vein—liver cancer	0.00947	0.251	CbGeAlD
Carvedilol—ABCB1—Doxorubicin—liver cancer	0.0083	0.0524	CbGbCtD
Carvedilol—CYP3A4—Sorafenib—liver cancer	0.00819	0.0517	CbGbCtD
Carvedilol—CYP2D6—Doxorubicin—liver cancer	0.00782	0.0493	CbGbCtD
Carvedilol—CYP3A4—Doxorubicin—liver cancer	0.00497	0.0314	CbGbCtD
Carvedilol—HIF1A—gall bladder—liver cancer	0.00375	0.0995	CbGeAlD
Carvedilol—HIF1A—embryo—liver cancer	0.00238	0.0631	CbGeAlD
Carvedilol—GJA1—embryo—liver cancer	0.0023	0.0612	CbGeAlD
Carvedilol—SELE—liver—liver cancer	0.00124	0.033	CbGeAlD
Carvedilol—VCAM1—liver—liver cancer	0.00114	0.0303	CbGeAlD
Carvedilol—HIF1A—liver—liver cancer	0.0011	0.0292	CbGeAlD
Carvedilol—GJA1—liver—liver cancer	0.00107	0.0283	CbGeAlD
Carvedilol—NDUFC2—liver—liver cancer	0.000928	0.0246	CbGeAlD
Carvedilol—VEGFA—liver—liver cancer	0.000841	0.0223	CbGeAlD
Carvedilol—XDH—liver—liver cancer	0.000749	0.0199	CbGeAlD
Carvedilol—ADRA1A—liver—liver cancer	0.000316	0.00838	CbGeAlD
Carvedilol—ADRA2C—liver—liver cancer	0.000301	0.00799	CbGeAlD
Carvedilol—ABCB1—embryo—liver cancer	0.000289	0.00768	CbGeAlD
Carvedilol—CYP1A2—liver—liver cancer	0.000261	0.00693	CbGeAlD
Carvedilol—CYP1A1—liver—liver cancer	0.000258	0.00684	CbGeAlD
Carvedilol—CYP2C9—liver—liver cancer	0.000248	0.00658	CbGeAlD
Carvedilol—Mental disability—Doxorubicin—liver cancer	0.000244	0.00249	CcSEcCtD
Carvedilol—Gastrointestinal pain—Sorafenib—liver cancer	0.000239	0.00245	CcSEcCtD
Carvedilol—Renal failure acute—Epirubicin—liver cancer	0.000238	0.00244	CcSEcCtD
Carvedilol—CYP2E1—liver—liver cancer	0.000235	0.00623	CbGeAlD
Carvedilol—Diabetes mellitus—Doxorubicin—liver cancer	0.000234	0.00239	CcSEcCtD
Carvedilol—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.000234	0.00239	CcSEcCtD
Carvedilol—Dermatitis exfoliative—Epirubicin—liver cancer	0.000233	0.00239	CcSEcCtD
Carvedilol—Urticaria—Sorafenib—liver cancer	0.000233	0.00238	CcSEcCtD
Carvedilol—Abdominal pain—Sorafenib—liver cancer	0.000231	0.00237	CcSEcCtD
Carvedilol—Body temperature increased—Sorafenib—liver cancer	0.000231	0.00237	CcSEcCtD
Carvedilol—Renal impairment—Epirubicin—liver cancer	0.000231	0.00237	CcSEcCtD
Carvedilol—Purpura—Epirubicin—liver cancer	0.000228	0.00234	CcSEcCtD
Carvedilol—Vascular purpura—Doxorubicin—liver cancer	0.000228	0.00233	CcSEcCtD
Carvedilol—Anaphylactoid reaction—Epirubicin—liver cancer	0.000227	0.00233	CcSEcCtD
Carvedilol—Cardiac failure—Epirubicin—liver cancer	0.000226	0.00231	CcSEcCtD
Carvedilol—Hypoglycaemia—Epirubicin—liver cancer	0.000226	0.00231	CcSEcCtD
Carvedilol—Cerebrovascular accident—Epirubicin—liver cancer	0.000225	0.0023	CcSEcCtD
Carvedilol—Hyponatraemia—Epirubicin—liver cancer	0.000221	0.00226	CcSEcCtD
Carvedilol—Renal failure acute—Doxorubicin—liver cancer	0.000221	0.00226	CcSEcCtD
Carvedilol—Pain in extremity—Epirubicin—liver cancer	0.00022	0.00225	CcSEcCtD
Carvedilol—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.00022	0.00225	CcSEcCtD
Carvedilol—Affect lability—Epirubicin—liver cancer	0.000217	0.00222	CcSEcCtD
Carvedilol—Migraine—Epirubicin—liver cancer	0.000217	0.00222	CcSEcCtD
Carvedilol—Dermatitis exfoliative—Doxorubicin—liver cancer	0.000216	0.00221	CcSEcCtD
Carvedilol—Hypersensitivity—Sorafenib—liver cancer	0.000216	0.00221	CcSEcCtD
Carvedilol—Renal impairment—Doxorubicin—liver cancer	0.000214	0.00219	CcSEcCtD
Carvedilol—Purpura—Doxorubicin—liver cancer	0.000211	0.00216	CcSEcCtD
Carvedilol—Anaphylactoid reaction—Doxorubicin—liver cancer	0.00021	0.00215	CcSEcCtD
Carvedilol—Asthenia—Sorafenib—liver cancer	0.00021	0.00215	CcSEcCtD
Carvedilol—Cardiac arrest—Epirubicin—liver cancer	0.000209	0.00214	CcSEcCtD
Carvedilol—Cardiac failure—Doxorubicin—liver cancer	0.000209	0.00213	CcSEcCtD
Carvedilol—Hypoglycaemia—Doxorubicin—liver cancer	0.000209	0.00213	CcSEcCtD
Carvedilol—Mood swings—Epirubicin—liver cancer	0.000209	0.00213	CcSEcCtD
Carvedilol—Cerebrovascular accident—Doxorubicin—liver cancer	0.000208	0.00213	CcSEcCtD
Carvedilol—Pruritus—Sorafenib—liver cancer	0.000207	0.00212	CcSEcCtD
Carvedilol—Blood creatinine increased—Epirubicin—liver cancer	0.000206	0.00211	CcSEcCtD
Carvedilol—Dehydration—Epirubicin—liver cancer	0.000205	0.00209	CcSEcCtD
Carvedilol—Hyponatraemia—Doxorubicin—liver cancer	0.000205	0.00209	CcSEcCtD
Carvedilol—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000204	0.00208	CcSEcCtD
Carvedilol—Pain in extremity—Doxorubicin—liver cancer	0.000204	0.00208	CcSEcCtD
Carvedilol—Orthostatic hypotension—Epirubicin—liver cancer	0.000201	0.00206	CcSEcCtD
Carvedilol—Migraine—Doxorubicin—liver cancer	0.000201	0.00205	CcSEcCtD
Carvedilol—Affect lability—Doxorubicin—liver cancer	0.000201	0.00205	CcSEcCtD
Carvedilol—Hypokalaemia—Epirubicin—liver cancer	0.0002	0.00205	CcSEcCtD
Carvedilol—Diarrhoea—Sorafenib—liver cancer	0.0002	0.00205	CcSEcCtD
Carvedilol—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000198	0.00203	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000198	0.00203	CcSEcCtD
Carvedilol—Nasopharyngitis—Epirubicin—liver cancer	0.000197	0.00201	CcSEcCtD
Carvedilol—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000194	0.00199	CcSEcCtD
Carvedilol—Cardiac arrest—Doxorubicin—liver cancer	0.000194	0.00198	CcSEcCtD
Carvedilol—Dizziness—Sorafenib—liver cancer	0.000194	0.00198	CcSEcCtD
Carvedilol—Mood swings—Doxorubicin—liver cancer	0.000193	0.00197	CcSEcCtD
Carvedilol—Blood creatinine increased—Doxorubicin—liver cancer	0.000191	0.00195	CcSEcCtD
Carvedilol—Influenza—Epirubicin—liver cancer	0.00019	0.00195	CcSEcCtD
Carvedilol—Dehydration—Doxorubicin—liver cancer	0.000189	0.00194	CcSEcCtD
Carvedilol—CYP3A4—liver—liver cancer	0.000189	0.00502	CbGeAlD
Carvedilol—Vomiting—Sorafenib—liver cancer	0.000186	0.0019	CcSEcCtD
Carvedilol—Orthostatic hypotension—Doxorubicin—liver cancer	0.000186	0.0019	CcSEcCtD
Carvedilol—CYP2D6—liver—liver cancer	0.000186	0.00494	CbGeAlD
Carvedilol—Hypokalaemia—Doxorubicin—liver cancer	0.000185	0.0019	CcSEcCtD
Carvedilol—Angina pectoris—Epirubicin—liver cancer	0.000185	0.0019	CcSEcCtD
Carvedilol—Rash—Sorafenib—liver cancer	0.000185	0.00189	CcSEcCtD
Carvedilol—Dermatitis—Sorafenib—liver cancer	0.000184	0.00189	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000183	0.00188	CcSEcCtD
Carvedilol—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000183	0.00188	CcSEcCtD
Carvedilol—Headache—Sorafenib—liver cancer	0.000183	0.00188	CcSEcCtD
Carvedilol—Bronchitis—Epirubicin—liver cancer	0.000183	0.00187	CcSEcCtD
Carvedilol—Nasopharyngitis—Doxorubicin—liver cancer	0.000182	0.00186	CcSEcCtD
Carvedilol—Pancytopenia—Epirubicin—liver cancer	0.000181	0.00185	CcSEcCtD
Carvedilol—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00018	0.00184	CcSEcCtD
Carvedilol—Upper respiratory tract infection—Epirubicin—liver cancer	0.000177	0.00181	CcSEcCtD
Carvedilol—Influenza—Doxorubicin—liver cancer	0.000176	0.0018	CcSEcCtD
Carvedilol—Pollakiuria—Epirubicin—liver cancer	0.000176	0.0018	CcSEcCtD
Carvedilol—Nausea—Sorafenib—liver cancer	0.000174	0.00178	CcSEcCtD
Carvedilol—Photosensitivity reaction—Epirubicin—liver cancer	0.000174	0.00178	CcSEcCtD
Carvedilol—Weight increased—Epirubicin—liver cancer	0.000173	0.00177	CcSEcCtD
Carvedilol—Weight decreased—Epirubicin—liver cancer	0.000172	0.00176	CcSEcCtD
Carvedilol—Hyperglycaemia—Epirubicin—liver cancer	0.000172	0.00176	CcSEcCtD
Carvedilol—Angina pectoris—Doxorubicin—liver cancer	0.000171	0.00175	CcSEcCtD
Carvedilol—Pneumonia—Epirubicin—liver cancer	0.000171	0.00174	CcSEcCtD
Carvedilol—Bronchitis—Doxorubicin—liver cancer	0.000169	0.00173	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000168	0.00172	CcSEcCtD
Carvedilol—Pancytopenia—Doxorubicin—liver cancer	0.000167	0.00171	CcSEcCtD
Carvedilol—Renal failure—Epirubicin—liver cancer	0.000167	0.00171	CcSEcCtD
Carvedilol—Urinary tract infection—Epirubicin—liver cancer	0.000165	0.00169	CcSEcCtD
Carvedilol—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000164	0.00167	CcSEcCtD
Carvedilol—Pollakiuria—Doxorubicin—liver cancer	0.000163	0.00166	CcSEcCtD
Carvedilol—Haematuria—Epirubicin—liver cancer	0.000162	0.00165	CcSEcCtD
Carvedilol—Photosensitivity reaction—Doxorubicin—liver cancer	0.000161	0.00164	CcSEcCtD
Carvedilol—Weight increased—Doxorubicin—liver cancer	0.00016	0.00164	CcSEcCtD
Carvedilol—Weight decreased—Doxorubicin—liver cancer	0.000159	0.00163	CcSEcCtD
Carvedilol—Sinusitis—Epirubicin—liver cancer	0.000159	0.00163	CcSEcCtD
Carvedilol—Hyperglycaemia—Doxorubicin—liver cancer	0.000159	0.00162	CcSEcCtD
Carvedilol—Pneumonia—Doxorubicin—liver cancer	0.000158	0.00161	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000156	0.00159	CcSEcCtD
Carvedilol—Bradycardia—Epirubicin—liver cancer	0.000155	0.00159	CcSEcCtD
Carvedilol—Renal failure—Doxorubicin—liver cancer	0.000154	0.00158	CcSEcCtD
Carvedilol—Haemoglobin—Epirubicin—liver cancer	0.000153	0.00157	CcSEcCtD
Carvedilol—Rhinitis—Epirubicin—liver cancer	0.000153	0.00156	CcSEcCtD
Carvedilol—Urinary tract infection—Doxorubicin—liver cancer	0.000153	0.00156	CcSEcCtD
Carvedilol—Haemorrhage—Epirubicin—liver cancer	0.000152	0.00156	CcSEcCtD
Carvedilol—Hypoaesthesia—Epirubicin—liver cancer	0.000152	0.00155	CcSEcCtD
Carvedilol—Pharyngitis—Epirubicin—liver cancer	0.000151	0.00155	CcSEcCtD
Carvedilol—Urinary tract disorder—Epirubicin—liver cancer	0.00015	0.00154	CcSEcCtD
Carvedilol—Oedema peripheral—Epirubicin—liver cancer	0.00015	0.00153	CcSEcCtD
Carvedilol—Haematuria—Doxorubicin—liver cancer	0.00015	0.00153	CcSEcCtD
Carvedilol—Urethral disorder—Epirubicin—liver cancer	0.000149	0.00153	CcSEcCtD
Carvedilol—Sinusitis—Doxorubicin—liver cancer	0.000147	0.00151	CcSEcCtD
Carvedilol—Visual impairment—Epirubicin—liver cancer	0.000147	0.0015	CcSEcCtD
Carvedilol—Erythema multiforme—Epirubicin—liver cancer	0.000144	0.00147	CcSEcCtD
Carvedilol—Bradycardia—Doxorubicin—liver cancer	0.000143	0.00147	CcSEcCtD
Carvedilol—Tinnitus—Epirubicin—liver cancer	0.000142	0.00145	CcSEcCtD
Carvedilol—Haemoglobin—Doxorubicin—liver cancer	0.000142	0.00145	CcSEcCtD
Carvedilol—Rhinitis—Doxorubicin—liver cancer	0.000141	0.00144	CcSEcCtD
Carvedilol—Haemorrhage—Doxorubicin—liver cancer	0.000141	0.00144	CcSEcCtD
Carvedilol—Hypoaesthesia—Doxorubicin—liver cancer	0.00014	0.00143	CcSEcCtD
Carvedilol—Pharyngitis—Doxorubicin—liver cancer	0.00014	0.00143	CcSEcCtD
Carvedilol—Urinary tract disorder—Doxorubicin—liver cancer	0.000139	0.00142	CcSEcCtD
Carvedilol—Oedema peripheral—Doxorubicin—liver cancer	0.000139	0.00142	CcSEcCtD
Carvedilol—Angiopathy—Epirubicin—liver cancer	0.000138	0.00141	CcSEcCtD
Carvedilol—Urethral disorder—Doxorubicin—liver cancer	0.000138	0.00141	CcSEcCtD
Carvedilol—Immune system disorder—Epirubicin—liver cancer	0.000138	0.00141	CcSEcCtD
Carvedilol—Mediastinal disorder—Epirubicin—liver cancer	0.000137	0.0014	CcSEcCtD
Carvedilol—Visual impairment—Doxorubicin—liver cancer	0.000136	0.00139	CcSEcCtD
Carvedilol—Alopecia—Epirubicin—liver cancer	0.000135	0.00138	CcSEcCtD
Carvedilol—ABCB1—liver—liver cancer	0.000134	0.00355	CbGeAlD
Carvedilol—Erythema multiforme—Doxorubicin—liver cancer	0.000133	0.00136	CcSEcCtD
Carvedilol—Malnutrition—Epirubicin—liver cancer	0.000133	0.00136	CcSEcCtD
Carvedilol—Tinnitus—Doxorubicin—liver cancer	0.000131	0.00134	CcSEcCtD
Carvedilol—Flatulence—Epirubicin—liver cancer	0.000131	0.00134	CcSEcCtD
Carvedilol—Tension—Epirubicin—liver cancer	0.00013	0.00133	CcSEcCtD
Carvedilol—Nervousness—Epirubicin—liver cancer	0.000129	0.00132	CcSEcCtD
Carvedilol—Back pain—Epirubicin—liver cancer	0.000128	0.00131	CcSEcCtD
Carvedilol—Angiopathy—Doxorubicin—liver cancer	0.000128	0.00131	CcSEcCtD
Carvedilol—Muscle spasms—Epirubicin—liver cancer	0.000127	0.0013	CcSEcCtD
Carvedilol—Immune system disorder—Doxorubicin—liver cancer	0.000127	0.0013	CcSEcCtD
Carvedilol—Mediastinal disorder—Doxorubicin—liver cancer	0.000127	0.0013	CcSEcCtD
Carvedilol—Vision blurred—Epirubicin—liver cancer	0.000125	0.00128	CcSEcCtD
Carvedilol—Alopecia—Doxorubicin—liver cancer	0.000125	0.00127	CcSEcCtD
Carvedilol—Ill-defined disorder—Epirubicin—liver cancer	0.000123	0.00126	CcSEcCtD
Carvedilol—Malnutrition—Doxorubicin—liver cancer	0.000123	0.00125	CcSEcCtD
Carvedilol—Anaemia—Epirubicin—liver cancer	0.000123	0.00125	CcSEcCtD
Carvedilol—Flatulence—Doxorubicin—liver cancer	0.000121	0.00124	CcSEcCtD
Carvedilol—Tension—Doxorubicin—liver cancer	0.00012	0.00123	CcSEcCtD
Carvedilol—Malaise—Epirubicin—liver cancer	0.00012	0.00122	CcSEcCtD
Carvedilol—Nervousness—Doxorubicin—liver cancer	0.000119	0.00122	CcSEcCtD
Carvedilol—Vertigo—Epirubicin—liver cancer	0.000119	0.00122	CcSEcCtD
Carvedilol—Syncope—Epirubicin—liver cancer	0.000119	0.00122	CcSEcCtD
Carvedilol—Leukopenia—Epirubicin—liver cancer	0.000119	0.00121	CcSEcCtD
Carvedilol—Back pain—Doxorubicin—liver cancer	0.000119	0.00121	CcSEcCtD
Carvedilol—Muscle spasms—Doxorubicin—liver cancer	0.000118	0.00121	CcSEcCtD
Carvedilol—Palpitations—Epirubicin—liver cancer	0.000117	0.0012	CcSEcCtD
Carvedilol—Loss of consciousness—Epirubicin—liver cancer	0.000117	0.00119	CcSEcCtD
Carvedilol—Cough—Epirubicin—liver cancer	0.000116	0.00118	CcSEcCtD
Carvedilol—Vision blurred—Doxorubicin—liver cancer	0.000116	0.00118	CcSEcCtD
Carvedilol—Convulsion—Epirubicin—liver cancer	0.000115	0.00117	CcSEcCtD
Carvedilol—Hypertension—Epirubicin—liver cancer	0.000114	0.00117	CcSEcCtD
Carvedilol—Ill-defined disorder—Doxorubicin—liver cancer	0.000114	0.00116	CcSEcCtD
Carvedilol—Anaemia—Doxorubicin—liver cancer	0.000113	0.00116	CcSEcCtD
Carvedilol—Arthralgia—Epirubicin—liver cancer	0.000113	0.00115	CcSEcCtD
Carvedilol—Myalgia—Epirubicin—liver cancer	0.000113	0.00115	CcSEcCtD
Carvedilol—Chest pain—Epirubicin—liver cancer	0.000113	0.00115	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000112	0.00115	CcSEcCtD
Carvedilol—Discomfort—Epirubicin—liver cancer	0.000112	0.00114	CcSEcCtD
Carvedilol—Malaise—Doxorubicin—liver cancer	0.000111	0.00113	CcSEcCtD
Carvedilol—Dry mouth—Epirubicin—liver cancer	0.00011	0.00113	CcSEcCtD
Carvedilol—Vertigo—Doxorubicin—liver cancer	0.00011	0.00113	CcSEcCtD
Carvedilol—Syncope—Doxorubicin—liver cancer	0.00011	0.00112	CcSEcCtD
Carvedilol—Leukopenia—Doxorubicin—liver cancer	0.00011	0.00112	CcSEcCtD
Carvedilol—Confusional state—Epirubicin—liver cancer	0.000109	0.00112	CcSEcCtD
Carvedilol—Palpitations—Doxorubicin—liver cancer	0.000108	0.00111	CcSEcCtD
Carvedilol—Anaphylactic shock—Epirubicin—liver cancer	0.000108	0.00111	CcSEcCtD
Carvedilol—Oedema—Epirubicin—liver cancer	0.000108	0.00111	CcSEcCtD
Carvedilol—Loss of consciousness—Doxorubicin—liver cancer	0.000108	0.0011	CcSEcCtD
Carvedilol—Infection—Epirubicin—liver cancer	0.000107	0.0011	CcSEcCtD
Carvedilol—Cough—Doxorubicin—liver cancer	0.000107	0.00109	CcSEcCtD
Carvedilol—Shock—Epirubicin—liver cancer	0.000106	0.00109	CcSEcCtD
Carvedilol—Convulsion—Doxorubicin—liver cancer	0.000106	0.00109	CcSEcCtD
Carvedilol—Thrombocytopenia—Epirubicin—liver cancer	0.000106	0.00108	CcSEcCtD
Carvedilol—Hypertension—Doxorubicin—liver cancer	0.000106	0.00108	CcSEcCtD
Carvedilol—Tachycardia—Epirubicin—liver cancer	0.000106	0.00108	CcSEcCtD
Carvedilol—Skin disorder—Epirubicin—liver cancer	0.000105	0.00107	CcSEcCtD
Carvedilol—Hyperhidrosis—Epirubicin—liver cancer	0.000105	0.00107	CcSEcCtD
Carvedilol—Arthralgia—Doxorubicin—liver cancer	0.000104	0.00107	CcSEcCtD
Carvedilol—Chest pain—Doxorubicin—liver cancer	0.000104	0.00107	CcSEcCtD
Carvedilol—Myalgia—Doxorubicin—liver cancer	0.000104	0.00107	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000104	0.00106	CcSEcCtD
Carvedilol—Discomfort—Doxorubicin—liver cancer	0.000103	0.00106	CcSEcCtD
Carvedilol—Anorexia—Epirubicin—liver cancer	0.000103	0.00105	CcSEcCtD
Carvedilol—Dry mouth—Doxorubicin—liver cancer	0.000102	0.00104	CcSEcCtD
Carvedilol—Hypotension—Epirubicin—liver cancer	0.000101	0.00103	CcSEcCtD
Carvedilol—Confusional state—Doxorubicin—liver cancer	0.000101	0.00103	CcSEcCtD
Carvedilol—Oedema—Doxorubicin—liver cancer	0.0001	0.00102	CcSEcCtD
Carvedilol—Anaphylactic shock—Doxorubicin—liver cancer	0.0001	0.00102	CcSEcCtD
Carvedilol—Infection—Doxorubicin—liver cancer	9.95e-05	0.00102	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Epirubicin—liver cancer	9.86e-05	0.00101	CcSEcCtD
Carvedilol—Shock—Doxorubicin—liver cancer	9.85e-05	0.00101	CcSEcCtD
Carvedilol—Thrombocytopenia—Doxorubicin—liver cancer	9.8e-05	0.001	CcSEcCtD
Carvedilol—Insomnia—Epirubicin—liver cancer	9.79e-05	0.001	CcSEcCtD
Carvedilol—Tachycardia—Doxorubicin—liver cancer	9.77e-05	0.000999	CcSEcCtD
Carvedilol—Skin disorder—Doxorubicin—liver cancer	9.72e-05	0.000994	CcSEcCtD
Carvedilol—Paraesthesia—Epirubicin—liver cancer	9.72e-05	0.000994	CcSEcCtD
Carvedilol—Hyperhidrosis—Doxorubicin—liver cancer	9.68e-05	0.00099	CcSEcCtD
Carvedilol—Dyspnoea—Epirubicin—liver cancer	9.65e-05	0.000986	CcSEcCtD
Carvedilol—Somnolence—Epirubicin—liver cancer	9.62e-05	0.000984	CcSEcCtD
Carvedilol—Anorexia—Doxorubicin—liver cancer	9.54e-05	0.000976	CcSEcCtD
Carvedilol—Dyspepsia—Epirubicin—liver cancer	9.52e-05	0.000974	CcSEcCtD
Carvedilol—Decreased appetite—Epirubicin—liver cancer	9.41e-05	0.000962	CcSEcCtD
Carvedilol—Hypotension—Doxorubicin—liver cancer	9.36e-05	0.000957	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Epirubicin—liver cancer	9.34e-05	0.000955	CcSEcCtD
Carvedilol—Fatigue—Epirubicin—liver cancer	9.33e-05	0.000954	CcSEcCtD
Carvedilol—Constipation—Epirubicin—liver cancer	9.25e-05	0.000946	CcSEcCtD
Carvedilol—Pain—Epirubicin—liver cancer	9.25e-05	0.000946	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Doxorubicin—liver cancer	9.12e-05	0.000933	CcSEcCtD
Carvedilol—Insomnia—Doxorubicin—liver cancer	9.06e-05	0.000926	CcSEcCtD
Carvedilol—Paraesthesia—Doxorubicin—liver cancer	8.99e-05	0.000919	CcSEcCtD
Carvedilol—Dyspnoea—Doxorubicin—liver cancer	8.93e-05	0.000913	CcSEcCtD
Carvedilol—Feeling abnormal—Epirubicin—liver cancer	8.92e-05	0.000912	CcSEcCtD
Carvedilol—Somnolence—Doxorubicin—liver cancer	8.9e-05	0.00091	CcSEcCtD
Carvedilol—Gastrointestinal pain—Epirubicin—liver cancer	8.85e-05	0.000905	CcSEcCtD
Carvedilol—Dyspepsia—Doxorubicin—liver cancer	8.81e-05	0.000901	CcSEcCtD
Carvedilol—Decreased appetite—Doxorubicin—liver cancer	8.7e-05	0.00089	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Doxorubicin—liver cancer	8.64e-05	0.000884	CcSEcCtD
Carvedilol—Fatigue—Doxorubicin—liver cancer	8.63e-05	0.000883	CcSEcCtD
Carvedilol—Urticaria—Epirubicin—liver cancer	8.6e-05	0.000879	CcSEcCtD
Carvedilol—Pain—Doxorubicin—liver cancer	8.56e-05	0.000875	CcSEcCtD
Carvedilol—Constipation—Doxorubicin—liver cancer	8.56e-05	0.000875	CcSEcCtD
Carvedilol—Body temperature increased—Epirubicin—liver cancer	8.55e-05	0.000875	CcSEcCtD
Carvedilol—Abdominal pain—Epirubicin—liver cancer	8.55e-05	0.000875	CcSEcCtD
Carvedilol—Feeling abnormal—Doxorubicin—liver cancer	8.25e-05	0.000844	CcSEcCtD
Carvedilol—Gastrointestinal pain—Doxorubicin—liver cancer	8.19e-05	0.000837	CcSEcCtD
Carvedilol—Hypersensitivity—Epirubicin—liver cancer	7.97e-05	0.000815	CcSEcCtD
Carvedilol—Urticaria—Doxorubicin—liver cancer	7.95e-05	0.000813	CcSEcCtD
Carvedilol—Abdominal pain—Doxorubicin—liver cancer	7.91e-05	0.000809	CcSEcCtD
Carvedilol—Body temperature increased—Doxorubicin—liver cancer	7.91e-05	0.000809	CcSEcCtD
Carvedilol—Asthenia—Epirubicin—liver cancer	7.76e-05	0.000794	CcSEcCtD
Carvedilol—Pruritus—Epirubicin—liver cancer	7.66e-05	0.000783	CcSEcCtD
Carvedilol—Diarrhoea—Epirubicin—liver cancer	7.4e-05	0.000757	CcSEcCtD
Carvedilol—Hypersensitivity—Doxorubicin—liver cancer	7.38e-05	0.000754	CcSEcCtD
Carvedilol—Asthenia—Doxorubicin—liver cancer	7.18e-05	0.000735	CcSEcCtD
Carvedilol—Dizziness—Epirubicin—liver cancer	7.16e-05	0.000732	CcSEcCtD
Carvedilol—Pruritus—Doxorubicin—liver cancer	7.08e-05	0.000724	CcSEcCtD
Carvedilol—Vomiting—Epirubicin—liver cancer	6.88e-05	0.000703	CcSEcCtD
Carvedilol—Diarrhoea—Doxorubicin—liver cancer	6.85e-05	0.0007	CcSEcCtD
Carvedilol—Rash—Epirubicin—liver cancer	6.82e-05	0.000698	CcSEcCtD
Carvedilol—Dermatitis—Epirubicin—liver cancer	6.82e-05	0.000697	CcSEcCtD
Carvedilol—Headache—Epirubicin—liver cancer	6.78e-05	0.000693	CcSEcCtD
Carvedilol—Dizziness—Doxorubicin—liver cancer	6.62e-05	0.000677	CcSEcCtD
Carvedilol—Nausea—Epirubicin—liver cancer	6.43e-05	0.000657	CcSEcCtD
Carvedilol—Vomiting—Doxorubicin—liver cancer	6.37e-05	0.000651	CcSEcCtD
Carvedilol—Rash—Doxorubicin—liver cancer	6.31e-05	0.000646	CcSEcCtD
Carvedilol—Dermatitis—Doxorubicin—liver cancer	6.31e-05	0.000645	CcSEcCtD
Carvedilol—Headache—Doxorubicin—liver cancer	6.27e-05	0.000641	CcSEcCtD
Carvedilol—Nausea—Doxorubicin—liver cancer	5.95e-05	0.000608	CcSEcCtD
Carvedilol—ADRB1—Signaling by GPCR—IL6—liver cancer	2.44e-06	1.58e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CASP3—liver cancer	2.43e-06	1.58e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MTOR—liver cancer	2.43e-06	1.58e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PIK3CB—liver cancer	2.43e-06	1.58e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—MTHFR—liver cancer	2.43e-06	1.58e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL2—liver cancer	2.43e-06	1.58e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—IL6—liver cancer	2.43e-06	1.57e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—KRAS—liver cancer	2.43e-06	1.57e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—AKT1—liver cancer	2.42e-06	1.57e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IL6—liver cancer	2.42e-06	1.57e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—IL6—liver cancer	2.42e-06	1.57e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—MTHFR—liver cancer	2.41e-06	1.56e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CASP3—liver cancer	2.4e-06	1.56e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PIK3CB—liver cancer	2.4e-06	1.56e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL2—liver cancer	2.4e-06	1.56e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCND1—liver cancer	2.39e-06	1.55e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—IL6—liver cancer	2.39e-06	1.55e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—JUN—liver cancer	2.38e-06	1.55e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CD—liver cancer	2.38e-06	1.55e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PPARA—liver cancer	2.38e-06	1.55e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP2E1—liver cancer	2.37e-06	1.54e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCND1—liver cancer	2.37e-06	1.54e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CTNNB1—liver cancer	2.37e-06	1.53e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—JUN—liver cancer	2.36e-06	1.53e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PPARA—liver cancer	2.36e-06	1.53e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—HRAS—liver cancer	2.36e-06	1.53e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—ALB—liver cancer	2.35e-06	1.53e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CTNNB1—liver cancer	2.34e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCND1—liver cancer	2.34e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—JUN—liver cancer	2.33e-06	1.51e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GSTM1—liver cancer	2.33e-06	1.51e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—HRAS—liver cancer	2.32e-06	1.51e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MMP9—liver cancer	2.32e-06	1.5e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CDKN1B—liver cancer	2.32e-06	1.5e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CTNNB1—liver cancer	2.31e-06	1.5e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CDKN1A—liver cancer	2.31e-06	1.5e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CD—liver cancer	2.3e-06	1.49e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MMP9—liver cancer	2.3e-06	1.49e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—AKT1—liver cancer	2.29e-06	1.49e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CDKN1A—liver cancer	2.29e-06	1.49e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—VEGFA—liver cancer	2.29e-06	1.48e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CDKN1B—liver cancer	2.28e-06	1.48e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—PIK3CA—liver cancer	2.28e-06	1.48e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SERPINE1—liver cancer	2.28e-06	1.48e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CASP3—liver cancer	2.27e-06	1.47e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MMP9—liver cancer	2.27e-06	1.47e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL2—liver cancer	2.27e-06	1.47e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—STAT3—liver cancer	2.26e-06	1.47e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CDKN1A—liver cancer	2.26e-06	1.47e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—IL6—liver cancer	2.26e-06	1.46e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—AKT1—liver cancer	2.26e-06	1.46e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MAPK8—liver cancer	2.26e-06	1.46e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—KRAS—liver cancer	2.25e-06	1.46e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—AKT1—liver cancer	2.25e-06	1.46e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—AKT1—liver cancer	2.24e-06	1.45e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CASP3—liver cancer	2.24e-06	1.45e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MAPK8—liver cancer	2.24e-06	1.45e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—AKT1—liver cancer	2.23e-06	1.45e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL2—liver cancer	2.23e-06	1.45e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—AKT1—liver cancer	2.23e-06	1.45e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—PIK3CA—liver cancer	2.23e-06	1.45e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—IL6—liver cancer	2.22e-06	1.44e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYCS—liver cancer	2.22e-06	1.44e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—RAF1—liver cancer	2.21e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCND1—liver cancer	2.21e-06	1.43e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CYP1A1—liver cancer	2.21e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MAPK8—liver cancer	2.21e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—JUN—liver cancer	2.21e-06	1.43e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CB—liver cancer	2.2e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—AKT1—liver cancer	2.2e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CTNNB1—liver cancer	2.19e-06	1.42e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GGT1—liver cancer	2.18e-06	1.41e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GOT1—liver cancer	2.18e-06	1.41e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCND1—liver cancer	2.18e-06	1.41e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—JUN—liver cancer	2.17e-06	1.41e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CG—liver cancer	2.17e-06	1.4e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MTOR—liver cancer	2.16e-06	1.4e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CB—liver cancer	2.16e-06	1.4e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CTNNB1—liver cancer	2.16e-06	1.4e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MMP9—liver cancer	2.15e-06	1.39e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CDKN1A—liver cancer	2.14e-06	1.39e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.12e-06	1.38e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MMP9—liver cancer	2.11e-06	1.37e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CDKN1A—liver cancer	2.11e-06	1.37e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MYC—liver cancer	2.1e-06	1.36e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TGFB1—liver cancer	2.1e-06	1.36e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PPARG—liver cancer	2.09e-06	1.36e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MAPK8—liver cancer	2.09e-06	1.35e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—VEGFA—liver cancer	2.08e-06	1.35e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—AKT1—liver cancer	2.08e-06	1.35e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CB—liver cancer	2.08e-06	1.35e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—PIK3CA—liver cancer	2.07e-06	1.34e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—VEGFA—liver cancer	2.06e-06	1.34e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—STAT3—liver cancer	2.06e-06	1.34e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—HRAS—liver cancer	2.06e-06	1.34e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—MTHFR—liver cancer	2.06e-06	1.33e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MAPK8—liver cancer	2.06e-06	1.33e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—RAF1—liver cancer	2.06e-06	1.33e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—AKT1—liver cancer	2.05e-06	1.33e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—STAT3—liver cancer	2.04e-06	1.33e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CG—liver cancer	2.04e-06	1.32e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—VEGFA—liver cancer	2.04e-06	1.32e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CDKN1B—liver cancer	2.03e-06	1.31e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CG—liver cancer	2.02e-06	1.31e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PPARA—liver cancer	2.02e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—STAT3—liver cancer	2.02e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MTOR—liver cancer	2.01e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CB—liver cancer	2.01e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—AKT1—liver cancer	2e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CASP3—liver cancer	1.99e-06	1.29e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL2—liver cancer	1.98e-06	1.29e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL6—liver cancer	1.97e-06	1.28e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PPARG—liver cancer	1.97e-06	1.28e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GSTP1—liver cancer	1.96e-06	1.27e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PPARG—liver cancer	1.95e-06	1.27e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KRAS—liver cancer	1.94e-06	1.26e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCND1—liver cancer	1.93e-06	1.25e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—JUN—liver cancer	1.93e-06	1.25e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—HMOX1—liver cancer	1.93e-06	1.25e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—VEGFA—liver cancer	1.93e-06	1.25e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MYC—liver cancer	1.92e-06	1.24e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—HRAS—liver cancer	1.92e-06	1.24e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CTNNB1—liver cancer	1.91e-06	1.24e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TGFB1—liver cancer	1.91e-06	1.24e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—STAT3—liver cancer	1.91e-06	1.24e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CD—liver cancer	1.9e-06	1.23e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MYC—liver cancer	1.9e-06	1.23e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—VEGFA—liver cancer	1.9e-06	1.23e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TGFB1—liver cancer	1.89e-06	1.23e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CDKN1B—liver cancer	1.88e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—ALB—liver cancer	1.88e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—STAT3—liver cancer	1.88e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MMP9—liver cancer	1.88e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MYC—liver cancer	1.87e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CDKN1A—liver cancer	1.87e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TGFB1—liver cancer	1.87e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—AKT1—liver cancer	1.86e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CASP3—liver cancer	1.85e-06	1.2e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL2—liver cancer	1.84e-06	1.2e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL6—liver cancer	1.83e-06	1.19e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MAPK8—liver cancer	1.83e-06	1.18e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—AKT1—liver cancer	1.82e-06	1.18e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.81e-06	1.18e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PIK3CA—liver cancer	1.8e-06	1.17e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PIK3CA—liver cancer	1.8e-06	1.17e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GSTM1—liver cancer	1.8e-06	1.17e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCND1—liver cancer	1.8e-06	1.17e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CD—liver cancer	1.79e-06	1.16e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—JUN—liver cancer	1.79e-06	1.16e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PIK3CA—liver cancer	1.79e-06	1.16e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CTNNB1—liver cancer	1.78e-06	1.15e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CD—liver cancer	1.78e-06	1.15e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MYC—liver cancer	1.77e-06	1.15e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KRAS—liver cancer	1.77e-06	1.15e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ALB—liver cancer	1.77e-06	1.15e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TGFB1—liver cancer	1.77e-06	1.15e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ALB—liver cancer	1.76e-06	1.14e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KRAS—liver cancer	1.75e-06	1.14e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MYC—liver cancer	1.75e-06	1.13e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MMP9—liver cancer	1.74e-06	1.13e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TGFB1—liver cancer	1.74e-06	1.13e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CDKN1A—liver cancer	1.74e-06	1.13e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KRAS—liver cancer	1.73e-06	1.12e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CG—liver cancer	1.73e-06	1.12e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—liver cancer	1.73e-06	1.12e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP1A1—liver cancer	1.7e-06	1.1e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MAPK8—liver cancer	1.7e-06	1.1e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—AKT1—liver cancer	1.69e-06	1.1e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—VEGFA—liver cancer	1.69e-06	1.09e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—STAT3—liver cancer	1.67e-06	1.08e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PPARG—liver cancer	1.67e-06	1.08e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CB—liver cancer	1.66e-06	1.08e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HRAS—liver cancer	1.65e-06	1.07e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KRAS—liver cancer	1.64e-06	1.06e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PIK3CA—liver cancer	1.63e-06	1.06e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KRAS—liver cancer	1.61e-06	1.05e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PIK3CA—liver cancer	1.61e-06	1.05e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PIK3CA—liver cancer	1.59e-06	1.03e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—MTHFR—liver cancer	1.59e-06	1.03e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL6—liver cancer	1.58e-06	1.03e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—liver cancer	1.57e-06	1.02e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—VEGFA—liver cancer	1.57e-06	1.02e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CB—liver cancer	1.56e-06	1.01e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—liver cancer	1.56e-06	1.01e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PPARA—liver cancer	1.56e-06	1.01e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MYC—liver cancer	1.55e-06	1.01e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—STAT3—liver cancer	1.55e-06	1.01e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CB—liver cancer	1.55e-06	1.01e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TGFB1—liver cancer	1.55e-06	1e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—liver cancer	1.54e-06	9.99e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CD—liver cancer	1.52e-06	9.86e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PIK3CA—liver cancer	1.51e-06	9.77e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HRAS—liver cancer	1.51e-06	9.76e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ALB—liver cancer	1.5e-06	9.73e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HRAS—liver cancer	1.49e-06	9.67e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PIK3CA—liver cancer	1.48e-06	9.61e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HRAS—liver cancer	1.47e-06	9.55e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—AKT1—liver cancer	1.47e-06	9.54e-06	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—AKT1—liver cancer	1.47e-06	9.52e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PIK3CA—liver cancer	1.46e-06	9.49e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—AKT1—liver cancer	1.46e-06	9.46e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—liver cancer	1.46e-06	9.45e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MYC—liver cancer	1.44e-06	9.35e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL6—liver cancer	1.44e-06	9.34e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TGFB1—liver cancer	1.44e-06	9.32e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—liver cancer	1.43e-06	9.3e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KRAS—liver cancer	1.43e-06	9.29e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL6—liver cancer	1.43e-06	9.26e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL6—liver cancer	1.41e-06	9.14e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HRAS—liver cancer	1.39e-06	9.04e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HRAS—liver cancer	1.37e-06	8.89e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CA—liver cancer	1.34e-06	8.71e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CG—liver cancer	1.33e-06	8.65e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL6—liver cancer	1.33e-06	8.65e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KRAS—liver cancer	1.33e-06	8.64e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—AKT1—liver cancer	1.33e-06	8.62e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CB—liver cancer	1.32e-06	8.59e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—AKT1—liver cancer	1.32e-06	8.54e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CA—liver cancer	1.32e-06	8.54e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL6—liver cancer	1.31e-06	8.51e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—AKT1—liver cancer	1.3e-06	8.43e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PPARG—liver cancer	1.29e-06	8.35e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—liver cancer	1.27e-06	8.26e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CA—liver cancer	1.27e-06	8.21e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—AKT1—liver cancer	1.23e-06	7.98e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CA—liver cancer	1.22e-06	7.93e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HRAS—liver cancer	1.22e-06	7.9e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—AKT1—liver cancer	1.21e-06	7.85e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—AKT1—liver cancer	1.2e-06	7.75e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—liver cancer	1.18e-06	7.67e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CD—liver cancer	1.17e-06	7.61e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL6—liver cancer	1.17e-06	7.56e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ALB—liver cancer	1.16e-06	7.51e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HRAS—liver cancer	1.13e-06	7.34e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—AKT1—liver cancer	1.1e-06	7.12e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL6—liver cancer	1.08e-06	7.02e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—AKT1—liver cancer	1.08e-06	6.98e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—AKT1—liver cancer	1.03e-06	6.71e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CB—liver cancer	1.02e-06	6.63e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CA—liver cancer	1.01e-06	6.56e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—AKT1—liver cancer	9.99e-07	6.48e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CA—liver cancer	9.53e-07	6.18e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CA—liver cancer	9.45e-07	6.13e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—AKT1—liver cancer	8.26e-07	5.36e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CA—liver cancer	8.08e-07	5.24e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—AKT1—liver cancer	7.79e-07	5.05e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—AKT1—liver cancer	7.72e-07	5.01e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—AKT1—liver cancer	6.6e-07	4.28e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CA—liver cancer	6.23e-07	4.04e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—AKT1—liver cancer	5.09e-07	3.3e-06	CbGpPWpGaD
